Skip to main content
. 2021 Jul 7;12:705485. doi: 10.3389/fimmu.2021.705485

Figure 3.

Figure 3

Atrosimab blocks acute TNF-induced inflammation in vivo. (A–C) C57BL/6 huTNFR1-k/i mice received i.v. injections of TNF (0.3 mg/kg), Atrosimab or FcΔab (30 mg/kg). (A) Body weight was determined and (B, C) blood samples were collected before treatment (0 h) and 1 h, 6 h, 24 h and 72 h after the injections. (B) IL-6 and (C) CRP levels in the serum were determined by ELISA. (D–F) C57BL/6 huTNFR1-k/i mice received i.v. injections of PBS, Atrosimab (30 mg/kg body weight) or FcΔab (30 mg/kg). TNF (0.3 mg/kg) was injected 30 minutes thereafter to induce acute inflammatory responses. (D) Body weight was determined and (E, F) blood samples were collected before treatment (0 h) and 1 h, 6 h, 24 h and 72 h after TNF injection. (E) IL-6 and (F) CRP levels in the serum were determined by ELISA. Individual values were excluded using the ROUT method of outlier identification or because they were below the detection limit (Q = 1%) or because they were below the detection limit of the ELISA. Mean ± SD, n=6. (A, C): **p < 0.01; (D): *p < 0.05 – TNF + PBS vs TNF + Atrosimab, #p < 0.05 – TNF + PBS vs TNF + FcΔab; (E, F): ns, not significant, **p < 0.01.